ANVV yields 2000000.00% · ABBV yields 3.06%● Live data
📍 ANVV pulled ahead of the other in Year 1
Combined, ANVV + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ANVV + ABBV for your $10,000?
Anvia Holdings Corporation, together with its subsidiaries, provides vocational training, consulting services, and education for construction tradesmen that need qualifications for roofing, plumbing, home renovation, electrical, and carpentry in Australia. The company also develops and commercializes Anvia Loyalty and Anvia Learning mobile applications. In addition, it offers life, business, and executive coaching platforms; educational courses in the field of English, fitness, business, and sports and recreation; and professional services, such as accounting and corporate advisory, recruitment, and digital content development services to small and medium companies. Further, the company develops software comprising human resource information, learning management, strategy management, competency management, and appraisal management systems, as well as customer loyalty mobile application on subscription basis for consumers and businesses. It markets and sells its products through Websites, social media, and digital and analog advertising channels. The company was formerly known as Dove Street Acquisition Corporation and changed its name to Anvia Holdings Corporation in January 2017. Anvia Holdings Corporation was founded in 2016 and is headquartered in Surry Hills, Australia.
Full ANVV Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.